FLRT3 Screening for Neuropathic Pain Suppressor Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain, particularly those involving the dorsal horn of the spinal cord, are inadequate due to the complexity of its molecular mechanisms, and there is a need for a novel target molecule to develop effective pain suppressors.
Innovation Solution
A screening method and pharmaceutical composition utilizing FLRT3, involving substances that inhibit FLRT3 expression, transport to the spinal cord, or binding to Unc5B, to suppress peripheral neuropathy-associated pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pain treatments (nonsteroidal antiinflammatory drugs and opioid analgesics) are used, then general pain relief is achieved, but they are ineffective for neuropathic pain
Solution Approach 1:
The patent segments the pain treatment approach by identifying specific molecular targets (FLRT3 and Unc5B) in the dorsal horn of the spinal cord that are specifically involved in neuropathic pain pathways. This allows differentiation between general pain mechanisms and neuropathic pain mechanisms, enabling targeted therapy that is effective specifically for neuropathic pain while maintaining broader treatment options for other pain types.
Solution Approach 2:
The patent introduces FLRT3 and Unc5B as intermediary molecular targets that mediate neuropathic pain signaling in the dorsal horn of the spinal cord. By targeting these specific intermediaries rather than using broad-spectrum analgesics, the treatment achieves high efficacy for neuropathic pain while preserving the ability to use conventional medications for other pain types, thus resolving the contradiction between reliability for neuropathic pain and adaptability to different pain types.
2Reliability
If the molecular mechanism of neuropathic pain is not clarified, then treatment options remain limited, but clarifying the complex mechanism requires extensive research
Solution Approach 1:
The patent performs preliminary action by identifying and validating FLRT3 and Unc5B as key molecular targets in the dorsal horn of the spinal cord before developing full therapeutic interventions. The screening method establishes a proof-of-concept platform that pre-validates the molecular mechanism, thereby reducing the time and resources required for subsequent drug development and clinical translation.
Solution Approach 2:
The patent implements a feedback mechanism through the screening method that uses FLRT3 and Unc5B as biomarkers to evaluate potential therapeutic compounds. This feedback system allows rapid assessment of compound efficacy at the molecular level, accelerating the drug development process and reducing the time from mechanism identification to effective treatment without compromising treatment effectiveness.
3Productivity
If a screening method using FLRT3 is developed, then pain suppressors can be discovered, but the complexity of FLRT3 expression and transport mechanisms increases the difficulty of the screening process
Solution Approach 1:
The patent extracts the key functional element (FLRT3) from the complex biological system and uses it as the basis for the screening method. By focusing on FLRT3 expression and its interaction with Unc5B as the primary screening criteria, the method simplifies the identification of pain suppressors while maintaining high productivity, avoiding the need to analyze the entire complex neural circuitry of the dorsal horn.
Solution Approach 2:
The patent applies local quality by focusing the screening method on specific properties of FLRT3 (its expression levels and binding to Unc5B) in the dorsal horn of the spinal cord, rather than attempting to screen for all possible pain-related mechanisms. This localized approach to screening maintains simplicity while achieving high productivity in discovering neuropathic pain suppressors.
Data Source
AI summary
The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.